H. Schoder et al., Effect of whole-body F-18-FDG PET imaging on clinical staging and management of patients with malignant lymphoma, J NUCL MED, 42(8), 2001, pp. 1139-1143
Citations number
37
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Medical Research Diagnosis & Treatment
Correct staging is important in selecting the appropriate treatment for lym
phoma patients. PET imaging with F-18-FDG is useful for staging of lymphoma
as well as for monitoring of therapy. However, to our knowledge, the clini
cal impact of PET on staging and management of lymphoma patients has not be
en reported. Methods: Standardized questionnaires were mailed to referring
physicians asking them whether and how the results of PET imaging had influ
enced clinical staging and management of the disease in their patients. Man
agement changes, when present, were classified as intermodality (e.g., medi
cal to surgical, surgical to radiation, medical to no treatment) or intramo
dality (e.g., altered medical, surgical, or radiotherapy approach). Results
: The referring physicians returned 52 of 108 questionnaires (48.1%). Physi
cians indicated that PET led to a change in the clinical stage in 44% of pa
tients: 21% were upstaged and 23% were downstaged. Findings of the PET exam
ination resulted in intermodality changes in management in 42% of patients,
in intramodality changes in 10%, and in a combination of the management ch
anges in 10%. Other, not further specified, treatment changes were reported
in 6% of patients. PET did not result in any management changes in only 32
% of patients. Conclusion: This survey-based study of referring physicians
indicates that FDG PET has a major impact on the management of lymphoma pat
ients, contributing to changes in clinical stage in 44% and changes in trea
tment in >60% of cases.